Comparison of Efficacy and Safety of Original and Biosimilar Adalimumab in Active Rheumatoid Arthritis in a Real-World National Cohort

Background and Objectives: Real-world evidence should reflect the evidence obtained from controlled trials; therefore, the study aimed to compare biosimilar adalimumab (bADA) to original adalimumab (oADA) in terms of efficacy and safety in a real-life national cohort of rheumatoid arthritis (RA) patients. Materials and Methods: The following study is a prospective observational study in which we analyzed patients treated with reimbursed biologics from the Romanian Registry of Rheumatic Diseases (RRBR). RA cases must fulfill the 2010 classification criteria, as well as specific inclusion and exclusion criteria. The RRBR database was queried for all RA patients starting oADA or bADA (FKB327, GP2017, MSB11022, SB5 available) from 2 May 2019 (the first bADA initiation) until 26 March 2022 (study search date). Results: The study included 441 patients who started oADA (48.3%) or bADA (51.7%) in the same time period. At baseline, patients starting bADA had a significantly higher mean age and lower prevalence of women. After the first six months of treatment, there were no significant differences between the oADA and bADA regarding rates of Boolean (15.0% vs. 12.3%, p = 0.401), DAS28-CRP (32.4% vs. 34.2%, p = 0.686) and SDAI (16.4% vs. 14.0%, p = 0.483) remission rates. There were 107 cases of adverse events (AE): 81.3% on oADA and 18.7% on bADA. Notably, 51.4% of AE were infections. Regarding severity, 49.5% of AEs were mild, 34.6% were moderate, and 15.9% were severe. Conclusion: Biosimilar adalimumab showed similar efficacy and safety to original adalimumab after the first six months of treatment in RA patients from a national registry.

[1]  L. Moreland,et al.  A review of biosimilars for rheumatoid arthritis. , 2022, Current opinion in pharmacology.

[2]  A. Alunno,et al.  Pathogenesis of rheumatoid arthritis: one year in review 2022. , 2022, Clinical and experimental rheumatology.

[3]  F. Cacciapaglia,et al.  Comparison of Adalimumab to Other Targeted Therapies in Rheumatoid Arthritis: Results from Systematic Literature Review and Meta-Analysis , 2022, Journal of personalized medicine.

[4]  Y. Lee,et al.  Relative remission rates of Janus kinase inhibitors in comparison with adalimumab in patients with active rheumatoid arthritis: a network meta-analysis , 2022, Zeitschrift für Rheumatologie.

[5]  M. Dougados,et al.  EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis , 2021, Annals of the Rheumatic Diseases.

[6]  Y. Lee,et al.  Comparison of the efficacy and safety of tocilizumab, sarilumab, and sirukumab in comparison with adalimumab as monotherapy in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials. , 2021, International journal of clinical pharmacology and therapeutics.

[7]  Y. Lee,et al.  Comparative efficacy and safety of adalimumab biosimilars and adalimumab in patients with rheumatoid arthritis presenting an insufficient response to methotrexate: a network meta-analysis , 2021, Zeitschrift für Rheumatologie.

[8]  Mengsi Liu,et al.  Efficacy and Safety of Adalimumab Biosimilars: Current Critical Clinical Data in Rheumatoid Arthritis , 2021, Frontiers in Immunology.

[9]  A. Blauvelt,et al.  Treatment with SDZ-ADL, an Adalimumab Biosimilar, in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis: Results of Patient-Reported Outcome Measures from Two Phase III Studies (ADMYRA and ADACCESS) , 2021, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy.

[10]  R. Caporali,et al.  Efficacy and safety of subcutaneous infliximab versus adalimumab, etanercept and intravenous infliximab in patients with rheumatoid arthritis: a systematic literature review and meta-analysis , 2020, Expert review of clinical immunology.

[11]  T. Huizinga,et al.  Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity , 2020, Rheumatology and Therapy.

[12]  M. Dougados,et al.  EULAR definition of difficult-to-treat rheumatoid arthritis , 2020, Annals of the Rheumatic Diseases.

[13]  Tsutomu Takeuchi,et al.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update , 2020, Annals of the Rheumatic Diseases.

[14]  K. Kawakami,et al.  A phase 1, randomized, open-label, single-dose study to assess the relative bioavailability of a subcutaneous dose of FKB327 when administered using a prefilled syringe, a prefilled auto-injector, or a vial with disposable syringe in healthy subjects , 2019, BMC Pharmacology and Toxicology.

[15]  M. Genovese,et al.  FKB327, an adalimumab biosimilar, versus the reference product: results of a randomized, Phase III, double-blind study, and its open-label extension , 2019, Arthritis Research & Therapy.

[16]  C. Codreanu,et al.  Efficacy and safety of original and biosimilar etanercept (SB4) in active rheumatoid arthritis - A comparison in a real-world national cohort. , 2019, Biologicals : journal of the International Association of Biological Standardization.

[17]  P. Vlachos,et al.  Safety of adalimumab biosimilar MSB11022 (acetate-buffered formulation) in patients with moderately-to-severely active rheumatoid arthritis , 2019, Clinical Rheumatology.

[18]  Bernice G Gershenson,et al.  Longterm, Real-world Safety of Adalimumab in Rheumatoid Arthritis: Analysis of a Prospective US-based Registry , 2019, The Journal of Rheumatology.

[19]  Donghoon Shin,et al.  Comparative pharmacokinetics of an adalimumab biosimilar SB5 administered via autoinjector or prefilled syringe in healthy subjects , 2018, Drug design, development and therapy.

[20]  J. Frampton.  SB5: An Adalimumab Biosimilar , 2018, BioDrugs.

[21]  R. Moots,et al.  Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis , 2018, Current Rheumatology Reports.

[22]  O. Hainzl,et al.  Comparative functional and pharmacological characterization of Sandoz proposed biosimilar adalimumab (GP2017): rationale for extrapolation across indications , 2018, Expert opinion on biological therapy.

[23]  A. Messori,et al.  Adalimumab biosimilar in rheumatoid arthritis: a total-evidence assessment to evaluate equivalence with the originator based on network meta-analysis. , 2018, Clinical and experimental rheumatology.

[24]  S. Bae,et al.  Comparative efficacy and safety of biosimilar adalimumab and originator adalimumab in combination with methotrexate in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials , 2018, Clinical Rheumatology.

[25]  M. Weinblatt,et al.  Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate‐to‐Severe Rheumatoid Arthritis , 2017, Arthritis & rheumatology.

[26]  A. Niewiarowski,et al.  Pharmacokinetics, safety, tolerability and immunogenicity of FKB327, a new biosimilar medicine of adalimumab/Humira, in healthy subjects , 2017, British journal of clinical pharmacology.

[27]  P. Vlachos,et al.  Comparison of the pharmacokinetics, safety, and immunogenicity of MSB11022, a biosimilar of adalimumab, with Humira® in healthy subjects , 2016, British journal of clinical pharmacology.

[28]  Juliana de Oliveira Costa,et al.  Adalimumab in rheumatoid arthritis treatment: a systematic review and meta-analysis of randomized clinical trials. , 2013, Revista brasileira de reumatologia.

[29]  G. Burmester,et al.  Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease , 2012, Annals of the rheumatic diseases.

[30]  David T Felson,et al.  UvA-DARE (Digital Academic Repository) American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials , 2011 .

[31]  A. Silman,et al.  UvA-DARE (Digital Academic Repository) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative Aletaha, , 2010 .

[32]  A. Silman,et al.  Rheumatoid arthritis classifi cation criteria : an American College of Rheumatology / European League Against Rheumatism collaborative initiative , 2010 .

[33]  R. Pontarolo,et al.  A systematic review and meta-analysis of the efficacy and safety of adalimumab for treating rheumatoid arthritis , 2010, Rheumatology International.

[34]  R. Pontarolo,et al.  Meta‐analysis of the Efficacy and Safety of Adalimumab, Etanercept, and Infliximab for the Treatment of Rheumatoid Arthritis , 2010, Pharmacotherapy.

[35]  P. V. van Riel,et al.  The Disease Activity Score and the EULAR response criteria. , 2005, Clinical and experimental rheumatology.

[36]  M. Uffmann,et al.  Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score , 2005, Arthritis research & therapy.

[37]  V. Strand,et al.  Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). , 2003, The Journal of rheumatology.

[38]  P. Tugwell,et al.  A simplified disease activity index for rheumatoid arthritis for use in clinical practice. , 2003, Rheumatology.

[39]  M. Prevoo,et al.  Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. , 1995, Arthritis and rheumatism.